Value-Based Insurance In Public Plan Could Change Approach To Rx Copays
Should the public plan option remain part of a final health care reform package, there is one line in the House version of the bill that could transform the insurance industry's approach to patient copayments for drugs
You may also be interested in...
A bill being sponsored by Sen. Kay Hutchison, R-Tex., aims to demonstrate that reducing Medicare beneficiaries' cost sharing for prescriptions will increase their adherence to medication therapy
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials